BioMARS 2.0: a robotic biologist for formulating and adapting biological experiments
Organizations: Suzhou Institute for Advanced Research, University of Science and Technology of China, Suzhou, Jiangsu, China. · School of Biomedical Engineering, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Abstract
Biological experimentation is not reducible to a single optimization problem, but requires decisions at multiple levels of abstraction: translating scientific knowledge into experimental procedures, adapting culture conditions to measured phenotypes and selecting interventions that test biological hypotheses. Automating experimental execution does not, by itself, determine which experiments should be performed next or how they should change in response to biological feedback. Here we introduce BioMARS, a human-in-the-loop multi-agent robotic system that connects knowledge-guided experimental decision-making with robotic execution and biological feedback. At the procedural level, BioMARS generated literature-grounded protocols and traceable action plans, improving expert-reviewed protocol quality scores across four model backends. At the parametric level, BioMARS used image-derived phenotypes from robotic retinal organoid culture to select subsequent experimental conditions, with higher reported scores in later rounds of the three-round experiment. At the intervention level, BioMARS nominated drug-repurposing candidates from biomedical evidence and advanced six candidates to wet-lab testing by researchers. Together, these studies demonstrate feedback-driven robotic biological experimentation within a framework that supports decisions about experimental procedures, culture conditions and biological interventions.
Figures & tables
Appendix figures & tables18 assets
Supplementary material from the paper’s appendix.
Appendix
| Function | Main arguments | Operation scope |
|---|---|---|
| Get container get_new_container_from_storage | Storage location; target workstation; container type | Acquire a new receiving vessel. Acquisition does not fill, coat or load it. |
| Discard container discard_container | Source workstation; container type | Dispose of a vessel designated as waste; distinct from returning a vessel to storage. |
| Get reagent get_reagent | Reagent identity; container type; target workstation | Retrieve an existing reagent or sample in its container. |
| Return reagent return_reagent | Reagent identity; container type; workstation | Return the same reagent or sample container to storage after use. |
| Transfer liquid transfer_liquid_between_workstations | Source and target workstation/types; volume; addressed wells; optional mixing | Transfer liquid or suspension to the specified receiver. Plate addressing follows the supported column or well convention. |
| Resuspend cells resuspend_cells_in_tube | Tube workstation and type; medium and volume fields | Mix cells already in a supported tube. This call does not itself add medium or adjust concentration. |
| Code | Maximum | Assessment criterion |
| C | 30 | Task-scope alignment: coverage of required functions, with deductions for explicitly unrelated experimental functions. |
| A | 30 | Content accuracy: fidelity of described operations and key conditions to the source. |
| L | 20 | Experimental logic: consistency of samples, branches, ordering, repetitions and input–output relationships. |
| S | 10 | Protocol structure: hierarchy, step localization, reading order, information accessibility and concision. |
| D | 10 | Procedural detail: retention of applicable parameters in the operations described. |
| Model | FlashRAG | BioMARS | Gain, points (95% CI) | Gain, % (95% CI) | Counts |
| GPT-4o | 73.80 | 86.71 | 12.91 (9.23, 16.53) | 17.5 (12.2, 23.1) | 40/1/6 |
| Qwen 3.6 Flash | 78.35 | 94.69 | 16.34 (13.44, 19.33) | 20.9 (16.6, 25.6) | 44/0/3 |
| DeepSeek V4 Flash | 81.98 | 93.89 | 11.92 (8.72, 15.28) | 14.5 (10.3, 19.2) | 40/1/6 |
| Gemini 3 Flash Preview | 76.51 | 90.11 | 13.60 (10.90, 16.40) | 17.8 (13.8, 22.1) | 42/1/4 |
| Dimension | Weight | Qwen | Qwen score | DeepSeek | DeepSeek score |
| Operation matching | 30 | 119 | 94.29 | 119 | 93.20 |
| Known arguments | 25 | 66 | 83.33 | 67 | 71.64 |
| Objects and handling | 25 | 111 | 76.58 | 112 | 80.36 |
| Required order | 10 | 30 | 96.67 | 32 | 93.75 |
| Unknown information | 10 | 47 | 97.87 | 47 | 95.74 |
| Total | 100 | 119 | 85.56 | 119 | 83.68 |
| Round | Algorithm | Selected pair | Mean | Median | Maximum score | Top-3 mean | Fraction | Fraction | Failures | High-noise |
| Round 1 | BO | BO–Round1–Plate1 BO–Round1–Plate2 | 0.429 | 0.418 | 0.798 | 0.725 | 0.000 | 0.000 | 1 | 1 |
| MASBO | MASBO–Round1–Plate2 MASBO–Round1–Plate3 | 0.435 | 0.418 | 0.974 | 0.757 | 0.100 | 0.100 | 1 | 2 | |
| Round 2 | BO | BO–Round2–Plate1 BO–Round2–Plate3 | 0.654 | 0.578 | 0.915 | 0.885 | 0.400 | 0.100 | 0 | 0 |
| MASBO | MASBO–Round2–Plate1 MASBO–Round2–Plate2 | 0.752 | 0.826 | 0.897 | 0.881 | 0.700 | 0.000 | 0 | 0 | |
| Round 3 | BO | BO–Round3–Plate2 BO–Round3–Plate3 | 0.764 | 0.855 | 0.920 | 0.906 | 0.700 | 0.200 | 1 | – |
| MASBO | MASBO–Round3–Plate2 MASBO–Round3–Plate3 | 0.923 | 0.941 | 0.949 | 0.949 | 1.000 | 0.800 | 0 | – |
| Region or unit | Role in analysis |
| Columns 1 and 12 | Control columns (W01/W12); excluded from candidate scores. |
| Rows A and H | Edge rows; excluded from candidate scores. |
| Rows B–G, columns 2–11 | Candidate region. Each column corresponds to one condition, with up to six technical-replicate wells per plate. |
| Blank or invalid measurements | Excluded from the within-plate mean; not converted to zero. |
| Plate1, Plate2 and Plate3 | Independent biological batches, each represented by one plate. Full identifiers specify algorithm, optimization round and plate (for example, BO–Round1–Plate1). |
| Final condition score | Average valid wells within each plate, then equally average the condition means from the highest-Pearson-correlation plate pair. |
| Candidate/ origin | System-generated hypothesis | Retrieved evidence from the same lineage |
|---|---|---|
| Ifenprodil One-hop link | Inhibition of GluN2B-containing NMDARs would reduce intracellular calcium overload and improve viability during NMDA exposure in retinal organoids. | Receptor pharmacology and developing rat cortical neurons support GluN2B-dependent antagonism and subtype-dependent ifenprodil sensitivity (rounds 2–5) [ 38 , 59 ] . These findings ground the receptor component of the hypothesis; organoid protection is an extrapolation. |
| Milnacipran HCl One-hop link | Non-competitive NMDAR antagonism would reduce GRIN1-associated calcium influx and subsequent inflammation. The system proposed IL-6 and TNF- measurements to test this response. | Retrieved literature reports non-competitive NMDAR antagonism by milnacipran itself [ 40 ] and NMDA-channel blockade and neuroprotection by conformationally restricted analogues (rounds 1–6) [ 60 , 41 ] . These findings support an NMDAR-related pharmacological rationale, but do not establish the proposed anti-inflammatory mechanism in organoids. |
| Agmatine sulfate One-hop link GRIN1 | Competitive antagonism at GRIN2B and activation of Nrf2 were proposed to reduce calcium influx and oxidative stress during NMDA exposure. | Polyamine-site binding and spinal NMDA-evoked calcium transients support receptor modulation (rounds 1–5) [ 39 , 61 ] . Rotenone-lesioned rats provide Nrf2-related evidence (rounds 1–5) [ 62 ] ; a retinal-neuroinflammation study reports protection in mice (round 5) [ 63 ] . Polyamine-site evidence does not establish competitive GRIN2B antagonism. |
| Stiripentol Predicted link | GRIN2A/2B modulation was refined into a hypothesis of enhanced GRIN2B-mediated signalling, improved mitochondrial dynamics and reduced oxidative stress in retinal organoids. | A drug-specific study reports neuronal protection and reduced sodium/calcium entry, but no detectable binding affinity for the tested glutamate receptors (round 4) [ 64 ] . Retinal-organoid evidence links mitochondrial oxidative stress to RGC death (round 5) [ 65 ] . Neither establishes the proposed enhancement of GRIN2B signalling. |
| Phenytoin Predicted link | GRIN2B/2D modulation would reduce reactive oxygen species and improve mitochondrial respiration during NMDA exposure. Proposed readouts were oxygen consumption and malondialdehyde levels. | Phenytoin produced modest electrocorticographic correction in a GRIN2D-variant mouse model (rounds 1–5) [ 66 ] . A neuronal-injury study links GluN2B signalling to mitophagy with THSG, a different compound (round 2) [ 67 ] . This supports a pathway rationale, not direct receptor engagement by phenytoin. |
| Memantine One-hop link GRIN1 | Selective inhibition of extrasynaptic NMDARs and GRIN1-dependent desensitization were proposed to reduce calcium overload and NMDA-induced organoid injury. | Retrieved studies report protection against NMDA-induced retinal degeneration (round 1) [ 68 ] , calcium-dependent NMDAR desensitization (rounds 1–4) [ 69 ] , and autophagy in ARPE-19 cells (rounds 3–4) [ 70 ] . Organoid-specific receptor selectivity remains part of the hypothesis. |
| Candidate/ source / rounds | Ref. | Study model and principal finding | Relevance to this study |
|---|---|---|---|
| Ifenprodil D1 R2–5 | [ 38 ] | Receptor pharmacology: selective antagonism of NR2B/GluN2B-containing NMDARs. | Direct pharmacological support; retinal organoids were not examined. |
| Ifenprodil D2 R2–5 | [ 59 ] | Developing rat cortical neurons: NMDAR subtypes differ in ifenprodil sensitivity. | Supports receptor-subtype dependence; extrapolation from developing cortical neurons is required. |
| Ifenprodil D3 R2–5 | [ 71 ] | A mouse PTSD model: Cheonwangbosimdan reduced PTSD-like behaviours through GluN2B-containing NMDAR antagonism. | Supports the target mechanism using a different compound and disease model. |
| Milnacipran HCl D1 R1–6 | [ 60 ] | Conformationally restricted milnacipran analogues show NMDA-channel-blocking activity. | Analogue-based support, rather than direct evidence for the parent drug. |
| Milnacipran HCl D2 R1–6 | [ 40 ] | Milnacipran itself has non-competitive NMDAR-antagonist activity; its conformationally restricted analogue PPDC is approximately 30-fold more potent. | Supports NMDAR pharmacology of the parent drug and analogue development; no retinal model was tested. |
| Milnacipran HCl D3 R1–6 | [ 41 ] | Conformationally restricted analogues block open NMDA channels and protect against NMDA-induced neurotoxicity. | Analogue potency and dose cannot be transferred directly to milnacipran. |
| Compound/experiment | Group | Mean | SD | Change (%) | Fig. 4 panel | |
|---|---|---|---|---|---|---|
| Ifenprodil 1 | Ctrl | 6 | 0.455 | 0.109 | – | d |
| NMDA | 5 | 0.363 | 0.083 | – | ||
| 1 M | 8 | 0.297 | 0.107 | -18.1 | ||
| 10 M | 8 | 0.318 | 0.104 | -12.3 | ||
| 100 M | 8 | 0.297 | 0.101 | -18.2 | ||
| Stiripentol 1 | Ctrl | 6 | 0.838 | 0.130 | – | d |
Autonomous Experimentation
Autonomous experimentation uses AI, active learning, and robotics to design, run, and interpret experiments with less human intervention.
See all 167 papers